We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+10.17%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$15.4B
AUM Growth
+$2.08B
Cap. Flow
+$1.36B
Cap. Flow %
8.86%
Top 10 Hldgs %
54.82%
Holding
115
New
20
Increased
35
Reduced
31
Closed
11

Top Buys

Rank Stock Value
1
APC
Anadarko Petroleum
APC
+$702M
2
CELG
Celgene Corp
CELG
+$666M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$459M
4
RHT
Red Hat Inc
RHT
+$333M
5
AGN
Allergan plc
AGN
+$138M

Top Sells

Rank Stock Value
1
TRU icon
TransUnion
TRU
+$181M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$173M
3
META icon
Meta Platforms (Facebook)
META
+$169M
4
BKNG icon
Booking.com
BKNG
+$157M
5
GG
Goldcorp Inc
GG
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 33.27%
2 Technology 17.66%
3 Communication Services 13.38%
4 Industrials 6.69%
5 Consumer Discretionary 4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
76
Tvardi Therapeutics
TVRD
$19M
$20.5M 0.13%
+26,426
New +$18.6M
VYGR icon
77
Voyager Therapeutics
VYGR
$189M
$20.4M 0.13%
750,000
-250,158
-25% -$5.72M
CCXI
78
DELISTED
ChemoCentryx, Inc.
CCXI
$18.6M 0.12%
2,000,000
+500,000
+33% +$5.79M
PTGX icon
79
Protagonist Therapeutics
PTGX
$8.73B
$18.2M 0.12%
1,500,000
-290,000
-16% -$3.21M
TECX
80
Tectonic Therapeutic
TECX
$550M
$16.8M 0.11%
86,346
+11,346
+15% +$2.45M
NSTG
81
DELISTED
NanoString Technologies, Inc.
NSTG
$10.6M 0.07%
350,000
-50,000
-13% -$1.32M
EIGR
82
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$10.6M 0.07%
+33,333
New +$11.5M
VOYA icon
83
Voya Financial
VOYA
$9.13B
$10.2M 0.07%
185,000
– –
VCYT icon
84
Veracyte
VCYT
$3.73B
$9.98M 0.06%
+350,000
New +$8.74M
PHAS
85
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$9.93M 0.06%
+756,961
New +$9.28M
TWST icon
86
Twist Bioscience
TWST
$6.19B
$8.91M 0.06%
+307,055
New +$8.12M
SVRA icon
87
Savara
SVRA
$1.11B
$8.24M 0.05%
3,475,000
+1,050,000
+43% +$9.33M
QURE icon
88
uniQure
QURE
$3.03B
$7.82M 0.05%
+100,000
New +$6.37M
MIST icon
89
Milestone Pharmaceuticals
MIST
$146M
$6.79M 0.04%
+250,000
New +$5.16M
CYCN icon
90
Cyclerion Therapeutics
CYCN
$15.2M
$6.23M 0.04%
+27,204
New +$7.7M
PSNL icon
91
Personalis
PSNL
$1.44B
$5.02M 0.03%
+184,932
New +$5.23M
PFNX
92
DELISTED
Pfenex Inc.
PFNX
$4.04M 0.03%
600,000
– –
GCVRZ
93
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.55M 0.02%
6,827,805
– –
AKRO
94
DELISTED
Akero Therapeutics
AKRO
$2.87M 0.02%
+150,000
New +$2.84M
APTX
95
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.24M 0.01%
670,000
– –
GOSS icon
96
Gossamer Bio
GOSS
$88.7M
$2.22M 0.01%
100,000
-277,852
-74% -$5.32M
LRMR icon
97
Larimar Therapeutics
LRMR
$427M
$2.14M 0.01%
150,000
– –
ASMB icon
98
Assembly Biosciences
ASMB
$524M
$1.35M 0.01%
8,333
– –
ADPT icon
99
Adaptive Biotechnologies
ADPT
$3.9B
$1.21M 0.01%
+25,000
New +$1.11M
OXY icon
100
Occidental Petroleum
OXY
$54.8B
$1.01M 0.01%
+20,000
New +$1.13M
1 2 3
4
5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Farallon Capital Management held 115 positions worth $15.4B, up 16% from $13.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Farallon Capital Management deployed $1.36B of net new capital in Q2 2019, opening 20 new positions and adding to 35 existing holdings. Its largest new stake was Anadarko Petroleum: 10,465,000 shares worth $738M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was TransUnion, an estimated $181M trimmed.

  • Farallon Capital Management's largest Q2 2019 buy was Anadarko Petroleum: 10,465,000 shares worth $738M.
  • Farallon Capital Management added most to Celgene Corp in Q2 2019, an estimated $666M increase.
  • Farallon Capital Management's biggest Q2 2019 reduction was TransUnion, cutting an estimated $181M.
  • Farallon Capital Management fully exited Goldcorp Inc in Q2 2019, selling an estimated $148M.
  • Farallon Capital Management's ten largest holdings make up 55% of its $15.4B portfolio in Q2 2019.
  • Farallon Capital Management opened 20 new positions and closed 11 in Q2 2019.
  • Farallon Capital Management's portfolio value rose 16% quarter-over-quarter to $15.4B.

Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.